Illumina (ILMN) is Downgraded by BofA/Merrill to Neutral

Illumina (ILMN) was Downgraded by BofA/Merrill to ” Neutral”. Earlier the firm had a rating of “Buy ” on the company shares. BofA/Merrill advised their investors in a research report released on Apr 19, 2016.

Many Wall Street Analysts have commented on Illumina. Shares were Downgraded by Canaccord Genuity on Feb 4, 2016 to ” Hold” and Lowered the Price Target to $ 160 from a previous price target of $205 .Shares were Reiterated by Deutsche Bank on Feb 3, 2016 to “Hold” and Lowered the Price Target to $ 160 from a previous price target of $178 .

On the company’s financial health, Illumina reported $0.81 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Feb 2, 2016. Analyst had a consensus of $0.82. The company had revenue of $591.55 million for the quarter, compared to analysts expectations of $586.94 million. The company’s revenue was up 15.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.

Illumina opened for trading at $173.17 and hit $178.77 on the upside on Monday, eventually ending the session at $178.13, with a gain of 2.59% or 4.49 points. The heightened volatility saw the trading volume jump to 13,81,938 shares. Company has a market cap of $26,185 M.

In a different news, on Apr 15, 2016, A Blaine Bowman (director) sold 5,000 shares at $172.96 per share price. According to the SEC, on Apr 14, 2016, Christian O Henry (EVP & Chief Commercial Officer) sold 12,500 shares at $175.00 per share price. On Apr 14, 2016, Jay T Flatley (Chief Executive Officer) sold 20,000 shares at $170.14 per share price, according to the Form-4 filing with the securities and exchange commission.

Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.


Leave a Reply

Illumina - Is it time to Sell?

Top Brokerage Firms are advising their investors on Illumina. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.